{"id":837033,"date":"2025-04-14T11:53:33","date_gmt":"2025-04-14T15:53:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/"},"modified":"2025-04-14T11:53:33","modified_gmt":"2025-04-14T15:53:33","slug":"cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/","title":{"rendered":"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics"},"content":{"rendered":"
\n

STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA) (the \u201cCompany\u201d), today announced that its Board of Directors (the \u201cBoard\u201d) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock.<\/p>\n

Cara\u2019s common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on\u00a0Wednesday, April 16, 2025 under the new name \u201cTvardi Therapeutics, Inc.\u201d and under the new symbol \u201cTVRD\u201d following the anticipated closing of the merger (the \u201cMerger\u201d) with Tvard Therapeutics, Inc. (\u201cTvardi\u201d), with a new CUSIP number 140755 307.<\/p>\n

The reverse stock split was approved by Cara\u2019s stockholders at Cara\u2019s special meeting of stockholders held on April 1, 2025, to be effected in the Board\u2019s discretion of not less than 1-for-2 and not more than 1-for-4. The final reverse stock split ratio of 1-for-3 was approved by the Board on April 1, 2025 and will become effective as of 4:01 p.m. Eastern Time on Tuesday, April 15, 2025.<\/p>\n

At the effective time of the reverse stock split, every three (3) issued and outstanding shares of the Company\u2019s common stock will automatically be combined into one (1) issued and outstanding share of the Company\u2019s common stock without any change in the par value per share. The reverse stock split will reduce the number of issued and outstanding shares of the Company\u2019s common stock from approximately 4.6 million to approximately 1.5 million (prior to giving effect to the closing of the Merger). The reverse stock split will not change the authorized number of shares of Cara\u2019s common stock.<\/p>\n

Fractional shares will not be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder\u2019s relative interest in the Company\u2019s equity securities, except for any adjustments for fractional shares.<\/p>\n

In addition, proportionate adjustments will be made to the number of shares underlying, and the exercise or conversion prices of, the Company\u2019s outstanding stock options, and to the number of shares of common stock issuable under the Company’s equity incentive plans.<\/p>\n

Following the closing of the Merger, the combined company’s total outstanding common stock is expected to be approximately 9.4 million shares.<\/p>\n

\n About Tvardi Therapeutics, Inc.<\/strong>\n <\/p>\n

Tvardi is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708).<\/p>\n

\n About\u00a0Cara Therapeutics<\/strong>\n <\/p>\n

Cara is a biopharmaceutical company that has been focused on leading a new treatment paradigm to improve the lives of patients suffering from chronic pruritus. Cara developed an IV formulation of difelikefalin, which is approved for the treatment of moderate-to-severe pruritus associated with advanced kidney disease in adults undergoing hemodialysis in\u00a0the United States, European Union, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.<\/p>\n

\n Forward-looking Statements<\/strong>\n <\/p>\n

Certain statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements regarding the anticipated completion and effects of the proposed Merger and the ability of the parties to consummate the Merger on the expected timeline or at all; the reverse stock split and the timing thereof; the impact of the reverse stock split on stockholders, including any adjustments that may result from the treatment of fractional shares, and option holders; the expected number of shares of common stock to be issued and outstanding following the reverse stock split and the Merger, and other statements regarding management\u2019s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them,. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include risks related to the Merger, including the completion of the Merger and the satisfaction (or waiver) of closing conditions; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the Company\u2019s actual reductions in spending as compared to anticipated cost reductions; the Company\u2019s costs of continuing to operate as a public company; and the other risks described more fully in Cara Therapeutics\u2019 filings with the\u00a0Securities and Exchange Commission, including the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the year ended\u00a0December 31, 2024\u00a0and its other documents subsequently filed with or furnished to the\u00a0Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made.\u00a0The Company\u00a0undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\n INVESTOR CONTACT:<\/strong>
\n
\n investor@caratherapeutics.com<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA) (the \u201cCompany\u201d), today announced that its Board of Directors (the \u201cBoard\u201d) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara\u2019s common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on\u00a0Wednesday, April 16, 2025 under the new name \u201cTvardi Therapeutics, Inc.\u201d and under the new symbol \u201cTVRD\u201d following the anticipated closing of the merger (the \u201cMerger\u201d) with Tvard Therapeutics, Inc. (\u201cTvardi\u201d), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara\u2019s stockholders at Cara\u2019s special meeting of stockholders held on April 1, 2025, to be effected in the … <\/p>\n

Continue reading “Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837033","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA) (the \u201cCompany\u201d), today announced that its Board of Directors (the \u201cBoard\u201d) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara\u2019s common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on\u00a0Wednesday, April 16, 2025 under the new name \u201cTvardi Therapeutics, Inc.\u201d and under the new symbol \u201cTVRD\u201d following the anticipated closing of the merger (the \u201cMerger\u201d) with Tvard Therapeutics, Inc. (\u201cTvardi\u201d), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara\u2019s stockholders at Cara\u2019s special meeting of stockholders held on April 1, 2025, to be effected in the … Continue reading "Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T15:53:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics\",\"datePublished\":\"2025-04-14T15:53:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/\"},\"wordCount\":920,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/\",\"name\":\"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==\",\"datePublished\":\"2025-04-14T15:53:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Market Newsdesk","og_description":"STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA) (the \u201cCompany\u201d), today announced that its Board of Directors (the \u201cBoard\u201d) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara\u2019s common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on\u00a0Wednesday, April 16, 2025 under the new name \u201cTvardi Therapeutics, Inc.\u201d and under the new symbol \u201cTVRD\u201d following the anticipated closing of the merger (the \u201cMerger\u201d) with Tvard Therapeutics, Inc. (\u201cTvardi\u201d), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara\u2019s stockholders at Cara\u2019s special meeting of stockholders held on April 1, 2025, to be effected in the … Continue reading \"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-14T15:53:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics","datePublished":"2025-04-14T15:53:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/"},"wordCount":920,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/","name":"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==","datePublished":"2025-04-14T15:53:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjAxNyM2ODY1MjEwIzUwMDEzMTA5Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-announces-1-for-3-reverse-stock-split-in-connection-with-the-proposed-merger-with-tvardi-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837033"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837033\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}